Literature DB >> 31327332

New/emerging psychoactive substances and associated psychopathological consequences.

F Schifano1, F Napoletano2, S Chiappini1, A Guirguis3, J M Corkery1, S Bonaccorso4, A Ricciardi4,5, N Scherbaum6, A Vento7,8,9.   

Abstract

BACKGROUND: The present paper provides an updated review of both the large number of new/novel/emerging psychoactive substances (NPS) and their associated psychopathological consequences. Focus was here given on identification of those NPS being commented in specialised online sources and the related short-/long-term psychopathological and medical ill-health effects.
METHODS: NPS have been identified through an innovative crawling/navigating software, called the 'NPS.Finder®', created in order to facilitate the process of early recognition of NPS online. A range of information regarding NPS, including chemical and street names; chemical formula; three-dimensional image and anecdotally reported clinical/psychoactive effects, were here made available.
RESULTS: Using the 'NPS.Finder®' approach, a few thousand NPS were here preliminarily identified, a number which is about 4-fold higher than those figures suggested by European and international drug agencies. NPS most commonly associated with the onset of psychopathological consequences included here synthetic cannabinoids/cannabimimetics; new synthetic opioids; ketamine-like dissociatives; novel stimulants; novel psychedelics and several prescription and over-the-counter medicines.
CONCLUSIONS: The ever-increasing changes in terms of recreational psychotropics' availability represent a relatively new challenge for psychiatry, as the pharmacodynamics and pharmacokinetics of many NPS have not been thoroughly understood. Health/mental health professionals should be informed about the range of NPS; their intake modalities; their psychoactive sought-after effects; the idiosyncratic psychotropics' combinations and finally, their medical and psychopathological risks.

Entities:  

Keywords:  Drug-induced psychosis; NPS; drug misuse; new psychoactive substances; prescribing drug misuse; psychedelics

Year:  2019        PMID: 31327332     DOI: 10.1017/S0033291719001727

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  15 in total

Review 1.  How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe.

Authors:  Raquel Santos-Toscano; Amira Guirguis; Colin Davidson
Journal:  Br J Clin Pharmacol       Date:  2020-02-23       Impact factor: 4.335

Review 2.  Understanding the UK Psychoactive Substances Act.

Authors:  Raymond G Hill
Journal:  Br J Clin Pharmacol       Date:  2020-01-03       Impact factor: 4.335

3.  Pharmacotherapy of Patients Taking New Psychoactive Substances: A Systematic Review and Analysis of Case Reports.

Authors:  Michal Ordak; Aleksandra Zmysłowska; Miłosz Bielski; Daniel Rybak; Maja Tomaszewska; Katarzyna Wyszomierska; Aleksandra Kmiec; Natalia Garlicka; Maria Zalewska; Michal Zalewski; Tadeusz Nasierowski; Elzbieta Muszynska; Magdalena Bujalska-Zadrozny
Journal:  Front Psychiatry       Date:  2021-04-23       Impact factor: 4.157

4.  Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS).

Authors:  Stefania Chiappini; Rachel Vickers-Smith; Amira Guirguis; John M Corkery; Giovanni Martinotti; Daniel R Harris; Fabrizio Schifano
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-27

5.  The Psychonauts' World of Cognitive Enhancers.

Authors:  Flavia Napoletano; Fabrizio Schifano; John Martin Corkery; Amira Guirguis; Davide Arillotta; Caroline Zangani; Alessandro Vento
Journal:  Front Psychiatry       Date:  2020-09-11       Impact factor: 4.157

6.  The clinical challenges of synthetic cathinones.

Authors:  Fabrizio Schifano; Flavia Napoletano; Davide Arillotta; Caroline Zangani; Liam Gilgar; Amira Guirguis; John Martin Corkery; Alessandro Vento
Journal:  Br J Clin Pharmacol       Date:  2020-02-03       Impact factor: 4.335

7.  Novel Opioids: Systematic Web Crawling Within the e-Psychonauts' Scenario.

Authors:  Davide Arillotta; Fabrizio Schifano; Flavia Napoletano; Caroline Zangani; Liam Gilgar; Amira Guirguis; John Martin Corkery; Eugenio Aguglia; Alessandro Vento
Journal:  Front Neurosci       Date:  2020-03-18       Impact factor: 4.677

8.  Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach.

Authors:  Valeria Catalani; Davide Arillotta; John Martin Corkery; Amira Guirguis; Alessandro Vento; Fabrizio Schifano
Journal:  Front Psychiatry       Date:  2021-02-09       Impact factor: 4.157

9.  Analyzing the Open/Deep Web to Better Understand the New/Novel Psychoactive Substances (NPS) Scenarios: Suggestions from CASSANDRA and NPS.Finder Research Projects.

Authors:  Fabrizio Schifano
Journal:  Brain Sci       Date:  2020-03-04

Review 10.  The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review.

Authors:  Safia Sharif; Amira Guirguis; Suzanne Fergus; Fabrizio Schifano
Journal:  Brain Sci       Date:  2021-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.